SCHEMBL869358

SCHEMBL869358

C/C(=C\Cc1c(C)c(O)c2ccccc2c1O)CCC[C@H](C)CCC[C@H](C)CCCC(C)C

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.57
PDE4A P27815 1/20 0.57
SNCA P37840 1/20 0.57
PDE3A Q14432 1/20 0.57
PTPN1 P18031 3/20 0.49
TRPV1 Q8NER1 1/20 0.38
VKORC1 Q9BQB6 1/20 0.37
PTPN2 P17706 1/20 0.37
CDC25B P30305 1/20 0.37
PSEN1 P49768 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28023376 1.00 PTGS1 (0.57) PTGS1PDE4ASNCAPDE3APTPN1
SCHEMBL29357300 1.00 PTGS1 (0.57) PTGS1PDE4ASNCAPDE3APTPN1
SCHEMBL29474878 1.00 PTGS1 (0.57) PTGS1PDE4ASNCAPDE3APTPN1
SCHEMBL25976874 0.95 PTGS1 (0.49) PTGS1PDE4ASNCAPDE3APTPN1
Pyrophosphoric Acid SCHEMBL9711032 0.91 PTGS1 (0.51) PTGS1PDE4ASNCAPDE3APTPN1
SCHEMBL19327403 0.88 PTGS1 (0.50) PTGS1PDE4ASNCAPDE3APTPN1
SCHEMBL22172548 0.86 PTGS1 (0.58) PTGS1PDE4ASNCAPDE3APTPN1
SCHEMBL22172508 0.86 PTGS1 (0.58) PTGS1PDE4ASNCAPDE3APTPN1
SCHEMBL13597513 0.86 PTPN1 (0.55) PTGS1PDE4ASNCAPDE3APTPN1
SCHEMBL2138789 0.86 PTPN1 (0.55) PTGS1PDE4ASNCAPDE3APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232004-A1 FRACTAL FORMULATIONS Nanogyre Sprl (BE) 2023-08-30 EP claimed
WO-2021078412-A1 FRACTAL FORMULATIONS MESSADEK JALLAL (BE) 2021-04-29 WO claimed
US-20190000862-A1 METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT HANANJA EHF (IS) 2019-01-03 US claimed
US-10144692-B2 Method of making vitamin K1 Sunny Pharmtech Inc. (TW) 2018-12-04 US claimed
US-9801855-B2 Nanocrystalline solid dispersion compositions and process of preparation thereof NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (NIPER) (IN) 2017-10-31 US claimed
US-20170260117-A1 Method of Making Vitamin K1 Sunny Pharmtech Inc. (TW) 2017-09-14 US claimed
EP-3207020-A1 METHOD OF MAKING VITAMIN K1 Sunny Pharmtech Inc., (TW) 2017-08-23 EP claimed
EP-2712613-B1 Vitamin K1 and uses thereof PHARMADAB D O O (SI) 2017-02-08 EP claimed
US-20160220505-A1 COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION SOLUBEST LTD. (IL) 2016-08-04 US claimed
WO-2016060670-A1 METHOD OF MAKING VITAMIN K1 Sunny Pharmtech Inc. (TW) 2016-04-21 WO claimed
US-20150132385-A1 NANOCRYSTALLINE SOLID DISPERSION COMPOSITIONS AND PROCESS OF PREPARATION THEREOF NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (NIPER) (IN) 2015-05-14 US claimed
EP-2822539-A2 NANOCRYSTALLINE SOLID DISPERSION COMPOSITIONS AND PROCESS OF PREPARATION THEREOF National Institute Of Pharmaceutical Education And Research (NIPER) (IN) 2015-01-14 EP claimed
WO-2013132457-A2 NANOCRYSTALLINE SOLID DISPERSION COMPOSITIONS AND PROCESS OF PREPARATION THEREOF NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (NIPER) (IN) 2013-09-12 WO claimed
EP-2200588-A1 COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION Solubest Ltd. (IL) 2010-06-30 EP claimed
WO-2009040818-A9 COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION SOLUBEST LTD (IL) 2010-05-20 WO claimed
US-20090098200-A1 COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION SOLUBEST LTD. (IL) 2009-04-16 US claimed
WO-2009040818-A1 COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION SOLUBEST LTD (IL) 2009-04-02 WO claimed
US-20230398132-A1 PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME GREENWOOD BRANDS, LLC (US) 2023-12-14 US disclosed
US-6294192-B1 PHARMACEUTICAL COMPOSITIONS CAPABLE OF SOLUBILIZING THERAPEUTICALLY EFFECTIVE AMOUNTS OF HYDROPHOBIC THERAPEUTIC AGENTS. CARRIER INCLUDES A HYDROPHILIC SURFACTANT AND A HYDROPHOBIC SURFACTANT, AQUEOUS DISPERSION LIPOCINE, INC. 2001-09-25 US disclosed
EP-0878549-A2 Process for the enzymatic production of fructosylated compounds Chemisches Laboratorium Dr. Kurt Richter GmbH (DE) 1998-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260117-A1 Method of Making Vitamin K1 PROC, VKORC1L1, VKORC1 PTGS1 684/4885PDE4A 4319/4885SNCA 2490/4885
US-20190000862-A1 METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT TMEM205, NUP205, PIGS PTGS1 555/4885PDE4A 1466/4885SNCA 3055/4885
US-10144692-B2 Method of making vitamin K1 PROC, VKORC1L1, VKORC1 PTGS1 684/4885PDE4A 4319/4885SNCA 2490/4885
US-20230398132-A1 PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME ABCB11, SLC47A1, SLC46A1 PTGS1 1193/4885PDE4A 395/4885SNCA 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.